Clinical trial
Clinical Evaluation of Nelarabine (506U78)in Japanese Patients With Leukemia or…
NCT00406757 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00406757 |
|---|---|
| Title | Clinical Evaluation of Nelarabine (506U78)in Japanese Patients With Leukemia or Lymphoma |
| Official title | Clinical Evaluation of 506U78 in Japanese Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukaemia, Lymphoblastic, Acute and Lymphoma |
| Intervention type | Drug |
| Interventions | Nelarabine injection 400mg/m2, Nelarabine injection 650mg/m2, Nelarabine injection 1000mg/m2, Nelarabine injection 1500mg/m2 |
| Enrollment | 13 |
| Start date | Aug 30, 2006 |
| Primary completion | Jul 15, 2009 |
| Completion | Jul 15, 2009 |
| First posted | Dec 4, 2006 |
| Last update posted | Nov 13, 2017 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: